Cerus (CERS) Net Margin (2010 - 2026)

Cerus (CERS) posted Net Margin of 5.19% for Q2 2026, down 69.04% sequentially from 3.07% in Q1 2026, and up 571.0% YoY from 0.77% in Q2 2025.

Cerus (CERS) Net Margin (2010 - 2026) Analysis & Trends

Cerus has reported Net Margin for 17 years, with the latest figure at 5.19% in Q2 2026.

Quarterly Net Margin rose 571.0% year-over-year to 5.19% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 2.29% (up 470.0% YoY) and the FY2025 annual result came in at 6.2%, up 222.0% from the prior year.
Net Margin retreated to 5.19% in Q2 2026 per CERS's latest filing, from 3.07% in the prior quarter.
Over five years, Net Margin peaked at 7.53% in Q4 2023 and troughed at 50.5% in Q1 2023.
A 5-year average of 14.35% and a median of 11.85% in 2025 frame the typical range for Net Margin.
The sharpest annual moves came in 2022 and 2023: Net Margin jumped 4186 bps in 2022, then plunged 1769 bps in 2023.
Over 5 years, Net Margin stood at 7.12% in 2022, then soared by 206 bps to 7.53% in 2023, then tumbled by 73 bps to 2.0% in 2024, then slumped by 161 bps to 1.23% in 2025, then sank by 324 bps to 5.19% in 2026.
According to Business Quant data, Net Margin over the past three periods registered 5.19%, 3.07%, and 1.23% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	7.37%
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	19.37%
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	12.84%
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	16.67%
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	13.87%
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	19.04%
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	10.84%
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	6.47%
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	13.47%
10	Cerus	560.58 Mn	504.32 Mn	29.53 Mn	-5.19%

Download Data